Fosamax Cost in Delaware 2026: What You Will Actually Pay for Alendronate

What Does Fosamax Cost in Delaware in 2026?

Generic alendronate is inexpensive. At most Delaware chain and independent pharmacies in 2026, a 30-day supply of the standard 70 mg once-weekly tablet runs approximately $15 cash-pay, while Merck's brand Fosamax carries a list price near $80 per month. The gap between those two numbers is one of the most patient-relevant facts in osteoporosis pharmacotherapy.

The switch to generic prescribing essentially closed the cost barrier for most Delaware residents. Alendronate lost its primary U.S. patent protection in 2008, and generic manufacturers flooded the market quickly. The FDA's current approved labeling for alendronate sodium tablets documents the 70 mg once-weekly formulation as the standard maintenance dose for postmenopausal osteoporosis, male osteoporosis, and glucocorticoid-induced osteoporosis. [1]

Price varies by pharmacy and by whether you use a discount card. GoodRx and similar programs frequently list alendronate 70 mg (4 tablets, one month supply) at $9 to $18 at Walmart, Walgreens, Rite Aid, and independent pharmacies across Wilmington, Dover, and Newark. [2] Costco and Sam's Club pharmacy counters in Delaware sometimes offer lower rates still, especially for members purchasing 90-day supplies.

Brand Fosamax at $80 per month rarely makes financial sense when the generic is bioequivalent and FDA-rated AB. The FDA Orange Book confirms AB-rated generic alendronate sodium as therapeutically equivalent to Fosamax. [1] Patients who prefer brand for any reason should ask their insurer whether brand is even on formulary, because many Delaware commercial plans have removed it entirely in favor of generic-only coverage.

Switching from brand to generic requires no dose adjustment. The active moiety, alendronic acid, is identical, and the clinical evidence base was built on the molecular compound, not the brand name. The Fracture Intervention Trial (FIT), published in JAMA in 1998 (N=2,027 women with low femoral-neck BMD), showed a 47% relative risk reduction in new vertebral fractures over three years at 5 mg daily (equivalent efficacy established for the 70 mg weekly formulation approved later). [3] That trial remains a cornerstone of bisphosphonate prescribing globally, and its results apply fully to any AB-rated generic.

Delaware Medicaid Coverage for Alendronate

Delaware Medicaid covers alendronate, but a prior authorization (PA) is required before the claim will process. The PA requirement is not unique to Delaware. Most state Medicaid programs apply step-therapy or PA criteria to bone-modifying agents to confirm a diagnosis of osteoporosis or documented fragility fracture before approving ongoing coverage. [4]

Delaware's Medicaid pharmacy program (administered through Diamond State Health Plan managed care organizations) places alendronate on its preferred drug list. Patients enrolled in Highmark Delaware, Molina Healthcare of Delaware, or United Healthcare Community Plan of Delaware should ask their plan's pharmacy benefit manager for the current preferred tier and PA form. Coverage approval typically requires documentation of a dual-energy X-ray absorptiometry (DXA) scan showing a T-score at or below -2.5, or a history of a fragility fracture, consistent with the National Osteoporosis Foundation's 2023 clinical practice guidelines. [5]

Once PA is approved, most Delaware Medicaid enrollees pay $0 to $3 per fill for generic alendronate. That cost-sharing figure is set by Delaware's Low-Income Subsidy (LIS) equivalent under Medicaid, and it applies at any enrolled pharmacy in the state.

Prescribers submitting a PA request should include the DXA report with T-score, the ICD-10 code (M81.0 for postmenopausal osteoporosis without pathological fracture is standard), any prior osteoporosis medications tried, and current calcium and vitamin D supplementation status. The American Association of Clinical Endocrinology (AACE) 2020 clinical practice guidelines state that "pharmacologic therapy is recommended for patients with osteoporosis-range T-score (T-score at or below -2.5) at the spine, femoral neck, or total hip." [6] That language maps directly to Medicaid PA criteria in most states, including Delaware.

Is Compounded Alendronate Legal in Delaware?

Compounding alendronate through a 503A pharmacy is legal in Delaware under a valid patient-specific prescription. The distinction between 503A and 503B facilities matters practically here.

Section 503A of the Federal Food, Drug, and Cosmetic Act governs traditional patient-specific compounding by state-licensed pharmacies. Delaware's Board of Pharmacy enforces state rules consistent with federal 503A standards, and alendronate is not on the FDA's list of drugs that may not be compounded for patient populations. [7] A Delaware-licensed prescriber may therefore write a prescription for compounded alendronate sodium for an individual patient, and a licensed 503A pharmacy may fill it. Common reasons patients seek compounded formulations include tablet-swallowing difficulty, a need for liquid suspension, or allergy to a tablet excipient.

503B outsourcing facilities, by contrast, produce large-scale compounded preparations without patient-specific prescriptions. Alendronate is not on FDA's current 503B drug shortage list, which limits 503B compounding to shortage situations, so 503B alendronate has a narrower legal pathway. [7] For most Delaware patients, the 503A route is the relevant one.

Cost through a 503A pharmacy varies by compounding formula and ingredients. Oral suspension formulations of alendronate 70 mg/100 mL, for example, may cost $20 to $50 per month before insurance. Some patients with comprehensive commercial coverage or Medicaid PA approval pay nothing out of pocket if their plan covers the compounded preparation. Delaware Medicaid coverage of compounded drugs requires the compounding pharmacy to be enrolled as a Medicaid provider, and the compound must meet PA criteria.

The FDA's guidance on compounding under section 503A is publicly documented and the agency updates the list of approved bulk drug substances periodically. [7] Prescribers and pharmacists in Delaware should verify the current 503A bulk-substance list before dispensing a compounded alendronate formulation that uses a non-finished drug ingredient.

Which Insurance Plans Cover Fosamax in Delaware?

Most Delaware commercial insurance plans cover generic alendronate as a Tier 1 or Tier 2 drug, producing a copay of $0 to $20 per fill depending on plan design. Brand Fosamax, if covered at all, typically sits on Tier 3 or Tier 4, with copays of $40 to $90 or more. [8]

Major payers operating in Delaware's individual and employer markets include Highmark Blue Cross Blue Shield Delaware, Aetna, Cigna, and United Healthcare. Each posts formulary documents on its website for the current plan year. Checking the formulary directly gives the tier placement, copay, and any step-therapy requirements for alendronate.

Employer-sponsored plans in Delaware are subject to federal ERISA rules and vary more widely than ACA marketplace plans. A plan may require a 90-day mail-order supply after the first two retail fills, which often cuts the per-dose cost. Patients on once-weekly alendronate use only four tablets per month, so a 90-day supply is 12 tablets. Mail-order dispensing of a 12-tablet package at Tier 1 can drop the effective monthly cost below $5 at some plans.

Medicare Part D covers alendronate. The Low-Income Subsidy (Extra Help) program reduces Part D cost-sharing to a fixed dollar copay, which in 2026 is $4.50 for generic drugs for full-subsidy beneficiaries. [4] Delaware residents enrolled in Medicare Advantage plans should verify that their specific plan's Part D formulary includes alendronate on the preferred generic tier.

The American College of Rheumatology's 2022 guidelines on glucocorticoid-induced osteoporosis specifically name oral bisphosphonates as the preferred first-line treatment for most patients on long-term corticosteroid therapy, which can support medical-necessity documentation when an insurer requests justification. [9]

What Is the Cheapest Way to Get Fosamax in Delaware?

Generic alendronate with a GoodRx or similar discount card at a high-volume pharmacy is frequently the lowest out-of-pocket option for uninsured or underinsured Delaware patients. Prices at Walmart's $4 generic list and Kroger's generic program sometimes include alendronate 70 mg, dropping cash cost below $10 per month.

The ranking of options from least to most expensive typically runs: manufacturer patient-assistance program (PAP) for qualifying patients at $0, Medicaid with approved PA at $0 to $3, discount card at Walmart or Costco at $9 to $15, standard commercial Tier 1 copay at $10 to $20, and brand Fosamax at list price at $80. The PAP offered through Merck's Merck Patient Assistance Program covers brand Fosamax for patients who meet income thresholds (generally at or below 200% to 400% of the federal poverty level) and who lack prescription coverage. [10]

NeedyMeds, RxAssist, and the Partnership for Prescription Assistance all list Delaware-applicable resources for alendronate. These are free directories of PAPs, state programs, and community health center discount dispensing. The Health Resources and Services Administration (HRSA) maintains a database of federally qualified health centers (FQHCs) in Delaware that dispense medications at reduced cost through the 340B drug pricing program. [11] FQHCs in Wilmington, Dover, Milford, and Georgetown participate in 340B, and patients qualifying for their sliding-scale fees may access alendronate at dramatically reduced prices.

The STEP trial and related bisphosphonate literature confirm that alendronate's clinical benefits appear at the standard 70 mg once-weekly dose. No published trial has shown superior fracture reduction at higher doses, meaning there is no clinical reason to pursue higher-cost extended regimens when standard generic dosing is appropriate. [3]

Can You Get Fosamax via Telehealth in Delaware?

Telehealth prescribing of alendronate is fully permitted in Delaware. State law does not restrict telehealth prescribing of non-controlled medications, and alendronate sodium is not a controlled substance under the DEA Controlled Substances Act or under Delaware law. [12]

A Delaware-licensed provider (or an out-of-state provider holding a Delaware license or practicing under Delaware's telehealth statutes) may evaluate a patient's osteoporosis risk, review a DXA report, and issue an alendronate prescription through a synchronous video visit or, in some circumstances, an asynchronous encounter depending on clinical appropriateness.

The American Telemedicine Association guidelines state that bone-loss pharmacotherapy prescribing is appropriate for telehealth when the prescriber can access prior diagnostic imaging, lab results, and medication history. [13] A DXA scan must still be ordered by an in-person or telehealth provider and performed at a physical imaging center. Delaware has DXA-capable facilities at ChristianaCare Health System in Wilmington, Bayhealth in Dover, and Beebe Healthcare in Lewes, among others.

HealthRX's telehealth platform operates in Delaware. Patients who complete an online intake, upload their most recent DXA report, and meet clinical criteria may receive an alendronate prescription sent directly to a Delaware pharmacy of their choice, including mail-order options. After prescription issuance, the treating provider follows up at 12 months with a repeat DXA to assess bone mineral density response, consistent with the Endocrine Society's 2019 pharmacologic management guidelines. [14]

How Delaware Patients Should Take Alendronate

The FDA-approved dosing for postmenopausal osteoporosis is 70 mg orally once weekly, taken first thing in the morning with 6 to 8 ounces of plain water, at least 30 minutes before any food, beverage, or other medication. [1] Patients must remain upright (sitting or standing) for at least 30 minutes after the dose to minimize esophageal irritation, the primary GI adverse effect of oral bisphosphonates.

The once-weekly schedule was validated in the FACT study, a 12-month randomized trial (N=1,258) that compared 70 mg once weekly to 10 mg daily and found equivalent BMD gains at the lumbar spine and femoral neck with comparable tolerability. [15] That trial established the weekly schedule used in current clinical practice.

Patients with creatinine clearance below 35 mL/min should avoid alendronate due to lack of safety data in severe renal impairment. The National Kidney Foundation recommends against bisphosphonate use when eGFR falls below 30 mL/min/1.73 m2. [16] Delaware nephrologists and primary care providers managing CKD patients with concurrent osteoporosis should consider denosumab or teriparatide after specialist consultation in that population.

Calcium and vitamin D co-supplementation is standard. The Endocrine Society's 2019 guidelines recommend 1,000 to 1 to 200 mg calcium daily from diet plus supplement, and 600 to 800 IU vitamin D daily for adults on bisphosphonate therapy, with higher vitamin D doses if 25-hydroxyvitamin D levels fall below 30 ng/mL. [14]

Drug holidays after 3 to 5 years of continuous oral bisphosphonate therapy are considered for low-to-moderate fracture risk patients. The American Society for Bone and Mineral Research (ASBMR) 2016 task force report recommends reassessing fracture risk after 5 years of oral bisphosphonate use to determine whether a drug holiday or continuation is appropriate. [17] A drug holiday does not mean permanent discontinuation. It typically runs 1 to 2 years, after which DXA results guide the restart decision.

Delaware-Specific Resources and Next Steps

Delaware residents without insurance or with high-deductible plans should contact the Delaware Insurance Commissioner's Consumer Services Division (302-674-7300) to identify plans with low generic-drug copays during open enrollment. The division also handles complaints about insurer PA denials for covered medications, including alendronate.

The Delaware Division of Public Health operates a Chronic Disease Prevention Program that includes bone health education and referrals to DXA screening at reduced cost for qualifying residents. Community health fairs in New Castle, Kent, and Sussex counties periodically offer free or low-cost DXA screening events. [18]

Patients who receive a PA denial from Delaware Medicaid have the right to appeal. The appeal window is 90 days from the denial notice. Providing the prescriber's clinical notes, the DXA T-score, and a copy of the AACE 2020 guidelines statement supporting pharmacotherapy at T-score at or below -2.5 strengthens the appeal record. [6]

For most Delaware patients with a confirmed osteoporosis diagnosis, generic alendronate 70 mg once weekly at a cash price of approximately $15 per month remains the most cost-accessible oral bisphosphonate in 2026, with Medicaid coverage dropping that cost to near zero after PA approval.